comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders - PubMed
5 hours ago
- #organoid
- #hematopoiesis
- #myeloma
- Introduction of comBO, a scalable iPSC-derived system for modeling lympho-myeloid hematopoiesis and stromal diversity.
- comBOs developed under physioxia in granular microgel scaffolds enhance scalability and reproducibility.
- Supports long-term lympho-myeloid potential in serial organoid re-seeding assays.
- Enables creation of 'chimeroids' with healthy or malignant donor cells for disease modeling.
- Recapitulates niche remodeling in multiple myeloma, identifying MIF signaling as a disease driver.
- MIF inhibition reduces inflammation and myeloma proliferation, suggesting therapeutic potential.
- Offers a physiologically faithful platform for disease modeling and therapeutic discovery in hematology and immunology.